// App-Quantinova.ai

: WEE1 KINASE IS A THERAPEUTIC TARGET IN MLL ACUTE LYMPHOBLASTIC LEUKEMIA THROUGH REGULATION OF RUNX1

Researchers

Presenter

  • Alena Malyukova

Principal Investigators

  • Mari Lahnalampi

  • Petri Plnen

  • Susanna Teppo

  • Kashyap Dave Dave

  • Olli Lohi

  • Merja Heinniemi

  • Olle Sangfelt

Medical Centers

  • Department of Vascular Biology, Karolinska Institute, Stockholm, Sweden

  • Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland

  • Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland

  • Tampere Center for Child Health Research,Tampere University and University Hospital, Tampere, Finland

  • iCellate Medical AB,Stockholm,Sweden

  • Department of Vascular Biology, Karolinska Institute, Stockholm, Sweden

Locations

  • Sweden

  • Finland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

  • ETV6-RUNX1

  • Histone-lysine N-methyltransferase 2A

  • WEE1 G2 Checkpoint Kinase

Drug/Treatment

  • AZD-1775

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved